Treatment

Injury (%)^b

Height (%)^c

Dry Weight (%)^c

Yield (%)^c

1 WAE

2 WAE

4 WAE

2^nd trifoliate

4^th trifoliate

Untreated control

0

0

0

100

100

100

100

Dimethenamid-P

5

5

1

97

101

95

103

S-metolachlor

13

9

1

99

101

96

103

Pyroxasulfone

6

4

1

99

100

102

100

Sulfentrazone

8

12

18

93

89

80

100

Sulfentrazone + dimethenamid-P

14 (13)

15 (17)

17 (18)

90 (91)

88 (90)

77 (80)

96 (97)

Sulfentrazone + S-metolachlor

20 (20)

18 (20)

14 (18)

91 (93)

90 (90)

80 (83)

99 (99)

Sulfentrazone + pyroxasulfone

13 (13)

13 (16)

14 (19)

89 (93)

89 (89)

80 (88)

97 (95)

Flumioxazin

12

8

3

101

104

99

110

Flumioxazin + dimethenamid-P

27 (16)

16 (13)

9 (4)

88 (99)

96 (105)

81 (96)

105 (114)

Flumioxazin + S-metolachlor

34 (23)

19 (16)

9 (4)

86 (101)

95 (106)

77 (101)

103 (112)

Flumioxazin + pyroxasulfone

24 (16)

16 (12)

10 (5)

89 (101)

95 (105)

83 (108)

102 (107)

Saflufenacil

4

7

5

101

99

100

103

Saflufenacil + dimethenamid-P

11 (9)

12 (11)

8 (6)

94 (98)

96 (100)

92 (96)

97 (101)

Saflufenacil + S-metolachlor

17 (16)

14 (15)

9 (6)

93 (101)

93 (100)

89 (99)

99 (102)

Saflufenacil + pyroxasulfone

7 (9)

10 (11)

10 (7)

90 (101)

92 (99)

86 (104)

95 (97)

LSD_0.05

3.9

3.3

3.6

5.8

4.2

8.4

6.6

Contrasts (P-values)^d

1) Untreated vs VLCFA inhibitors

0.0001

0.0001

0.49

0.39

0.72

0.38

0.51

2) Untreated vs Protox inhibitors

0.0001

0.0001

0.0001

0.42

0.08

0.03

0.09

3) Sulfentrazone vs sulfentrazone

+ a VLCFA inhibitor

0.0001

0.008

0.04

0.29

0.79

0.70

0.28

4) Flumioxazin vs flumioxazin

+ a VLCFA inhibitor

0.0001

0.0001

0.0001

0.0001

0.0001

0.0001

0.01

5) Saflufenacil vs saflufenacil

+ a VLCFA inhibitor

0.0001

0.0001

0.03

0.0004

0.004

0.009

0.03